Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H12ClNO2.ClH |
| Molecular Weight | 250.122 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC[C@H](CC(O)=O)C1=CC=C(Cl)C=C1
InChI
InChIKey=WMNUVYYLMCMHLU-QRPNPIFTSA-N
InChI=1S/C10H12ClNO2.ClH/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14;/h1-4,8H,5-6,12H2,(H,13,14);1H/t8-;/m0./s1
| Molecular Formula | C10H12ClNO2 |
| Molecular Weight | 213.661 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Arbaclofen (STX209, R-baclofen), a selective agonist of GABA-B receptors, has been investigated in clinical trials for the treatment of autism spectrum disorder ASD, phase II and for the treatment of patients with fragile X syndrome in phase III. As a result, the drug did not meet the primary outcome of improved social avoidance in FXS in either study. In spite of positive results in some children with ASD, further study will be needed to replicate and extend these initial findings. Arbaclofen has also been investigated in phase III clinical trials as a treatment for spasticity due to multiple sclerosis.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. | 1997 Mar 20 |
|
| Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. | 2012 Sep 19 |
|
| Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder. | 2014 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:05:23 GMT 2023
by
admin
on
Fri Dec 15 16:05:23 GMT 2023
|
| Record UNII |
8703929ITD
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29696
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
63701-55-3
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY | |||
|
8703929ITD
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY | |||
|
44601
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY | |||
|
C90888
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY | |||
|
m2200
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID40213112
Created by
admin on Fri Dec 15 16:05:23 GMT 2023 , Edited by admin on Fri Dec 15 16:05:23 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |